One in nine may get delayed large local reaction after Moderna vaccine

One in nine may get delayed large local reaction after moderna vaccine

Women and individuals aged 30 to 69 years may be at higher risk for delayed large local reaction (DLLR) following the mRNA-1273 vaccine against COVID-19 (Moderna), according to a report published online June 1 in JAMA Dermatology.

Toshihide Higashino, M.D., Ph.D., from National Defense Medical College in Tokyo, and colleagues examined associations between sex and age and susceptibility of DLLRs after mRNA-1273 vaccination. Analysis included 5,893 individuals receiving the mRNA-1273 (May 24 to November 30, 2021).

The researchers found that 12.7 percent of participants experienced DLLR symptoms after the first dose of the mRNA-1273 vaccine. Symptoms were classified as mild and not considered as contraindications to the vaccine. Women had higher incidence rates of DLLR than men (22.4 versus 5.1 percent; odds ratio [OR], 5.30). Additionally, compared to participants aged 18 to 29 years (9.0 percent), the incidence rate was significantly higher among participants aged 30 to 39 years (14.3 percent; odds ratio, 1.68), 40 to 49 years (15.8 percent; odds ratio, 1.89), 50 to 59 years (14.9 percent; odds ratio, 1.76), and 60 to 69 years (12.6 percent; odds ratio, 1.45).

"The association between and susceptibility of DLLR suggests that the condition is a type IV allergic skin reaction," the authors write.

More information: Toshihide Higashino et al, Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan, JAMA Dermatology (2022). DOI: 10.1001/jamadermatol.2022.2088

Journal information: JAMA Dermatology

© 2022 HealthDay. All rights reserved.

Citation: One in nine may get delayed large local reaction after Moderna vaccine (2022, June 13) retrieved 14 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

50-µg mRNA-1273 safe, effective for children aged 6 to 11 years


Feedback to editors